Descovy Side Effects
The most common side effect of Descovy for HIV treatment is nausea, while for HIV prevention (PrEP) it is diarrhea 1.
Serious Side Effects
Kidney Problems
New or worsening kidney problems, including kidney failure, can occur with Descovy. Your healthcare provider should perform blood and urine tests to check kidney function before starting and during treatment 1. Tenofovir alafenamide (TAF, the tenofovir component in Descovy) has significantly less kidney toxicity compared to the older tenofovir disoproxil fumarate (TDF) formulation 2, 3. However, monitoring remains important, particularly in patients with pre-existing kidney disease or those taking other nephrotoxic medications.
Lactic Acidosis
Too much lactic acid in the blood (lactic acidosis) is a serious but rare medical emergency that can lead to death 1. Seek immediate medical attention if you experience:
- Weakness or unusual fatigue
- Unusual muscle pain
- Shortness of breath or rapid breathing
- Stomach pain with nausea and vomiting
- Cold or blue hands and feet
- Dizziness or lightheadedness
- Fast or abnormal heartbeat
While lactic acidosis was more commonly associated with older tenofovir formulations, cases have been reported with TAF, particularly in overdose situations 4.
Severe Liver Problems
In rare cases, severe liver problems can occur that may lead to death 1. Warning signs include:
- Yellowing of skin or whites of eyes (jaundice)
- Dark "tea-colored" urine
- Light-colored stools
- Loss of appetite for several days or longer
- Nausea or stomach pain
Immune Reconstitution Syndrome
When starting HIV treatment, your immune system may strengthen and begin fighting infections that were previously hidden in your body. Report any new symptoms of infection to your healthcare provider 1.
Common Side Effects
For HIV Treatment
For HIV Prevention (PrEP)
- Diarrhea (most common) 1
Additional Considerations from Real-World Data
Neuropsychiatric Effects
A systematic review found that headache, dizziness, insomnia, and depression were common neuropsychiatric adverse events in tenofovir-based regimens 5. Specifically, tenofovir (with or without emtricitabine) showed an increased risk of dizziness compared to placebo (odds ratio 1.32,95% CI 1.09-1.59) 5.
Weight Gain
Weight gain has been observed with TAF-containing regimens. In the DISCOVER trial at 96 weeks, participants on emtricitabine/tenofovir alafenamide gained more weight than those on the older formulation (median 1.7 kg vs 0.5 kg) 6. This is an important consideration for long-term metabolic health.
Bone and Renal Safety Advantages
Descovy demonstrates superior bone mineral density and renal safety profiles compared to older tenofovir formulations 6, 3. In clinical trials, emtricitabine/tenofovir alafenamide was superior to emtricitabine/tenofovir disoproxil fumarate in all six prespecified bone mineral density and renal biomarker safety endpoints 3.
Metabolic Effects
Some real-world pharmacovigilance data suggest potential signals for metabolic effects including increased lipids and possible pancreatitis, though these require further investigation 7.
Important Warnings
- Do not stop taking Descovy without consulting your healthcare provider, as this can lead to viral resistance in HIV treatment or increased infection risk in PrEP 1
- Inform your healthcare provider of all medications you take, as drug interactions can occur 1
- Regular monitoring is essential: kidney function tests should be performed before starting and periodically during treatment 8
Discontinuation Rates
Descovy is generally well-tolerated with low discontinuation rates. In clinical trials, only 1-2% of participants discontinued due to adverse events 3, 9. Real-world studies in Spain confirmed low rates of treatment discontinuations due to adverse events or drug-drug interactions 10.